Results presented at the Society of Gynecologic Oncology (SGO) annual meeting have put two PD-1 inhibitors on course for a battle in the advanced endometrial ca 29 March 2023
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical 22 March 2023
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Eli Lilly’s (NYSE: LLY) oncology company, Loxo@Lilly, has announced updated clinical data from the global Phase I/II BRUIN trial of pirtobrutinib. 13 December 2022
USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) has announced positive new and updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 trial of its ly 12 December 2022
With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie combined in 2021, the blood cancer drug has already changed the standard o 12 December 2022
At the 2022 American Society of Hematology (ASH) annual meeting, new results for Tecvayli (teclistamab) have been presented by US pharma giant Johnson & Johnson 12 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.